CML patients who have achieved a major molecular response (MMR, BCR/ABL ≤ 0.1%) or molecular response4.5 (MR4.5, BCR/ABL ≤ 0.0032%) show a larger proportion of mature, cytolytic CD57+CD62L− NK cells in PB with repertoires of activating and inhibitory receptors on NK cells restored to expression levels found in HIs [8]. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.